IDEAYA Biosciences, Inc. (FRA:30J)

Market Cap	2.38B +14.5%
Revenue (ttm)	186.28M +3,024.4%
Net Income	-96.84M
EPS	-1.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	20
Open	28.00
Previous Close	26.00
Day's Range	28.00 - 28.00
52-Week Range	12.80 - 32.20
Beta	n/a
RSI	51.45
Earnings Date	Feb 13, 2026

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 145
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30J

Financial Performance

In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.

Financial numbers in USD